Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Presentation at AJ Bell and Shares Spotlight Event

19th May 2025 07:00

RNS Number : 0777J
AOTI, Inc.
19 May 2025
 

19 May 2025

 

 

AOTI, INC. (the "Company" or "Group" or "AOTI")

 

Presentation at AJ Bell and Shares Spotlight Event

 

 

AOTI, INC. (AIM: AOTI), a medical technology group focused on the durable healing of wounds and the prevention of amputations, will be presenting at the AJ Bell and Shares Spotlight Event in London, UK on Tuesday, 20 May 2025. The event will start at 17:15 BST and investors can register to attend here: https://ajbell.eventsair.com/shares-spotlight-events-london-20052025/200525/Site/Register.

 

Dr. Mike Griffiths, Chief Executive Officer of AOTI, will be presenting an overview of the Company and will be available to take questions during the event.

 

 

ENDS

 

AOTI, INC.

Dr. Mike Griffiths, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

 

 

+44 (0)20 3727 1000

[email protected]

FTI Consulting (Financial PR & IR)

Ben Atwell, Simon Conway,

Natalie Garland-Collins, Alex Davis

 

+44 (0)20 3727 1000

[email protected]

 

ABOUT AOTI, INC.

 

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2®) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO2® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. Also see www.aotinc.net

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAAFMITMTJBBFA

Related Shares:

Aoti, Inc.
FTSE 100 Latest
Value8,774.26
Change1.88